Creo Medical Group Plc (LSE:CREO) has spent much of 2026 reorganising its operations, and the latest set of announcements suggests the medical device developer is trying to pair faster sales growth with a lighter cost base. Its first-half 2026 update reported Revenue growth of around 45% alongside a cost reduction of roughly 15%, while the company has also raised fresh Share Capital and moved to outsource manufacturing.

For investors following smaller healthcare names on London's junior market, the combination of growth, restructuring and new funding has placed the group firmly back in focus.

What the Company Does

Creo Medical is a UK-based medical technology Business that develops devices for minimally invasive surgical endoscopy. Its products use advanced energy, including microwave and radiofrequency, to allow clinicians to cut, coagulate and ablate tissue through flexible endoscopes. The aim is to give hospitals less invasive alternatives to some conventional surgical procedures, which can shorten patient recovery times.

The group sells its technology to hospitals and has worked with distribution and commercial partners in several markets. Its product range includes MicroBlate Fine, a device designed for the ablation of soft tissue.

Latest Developments

Several announcements during 2026 have charted the group's change of direction. Creo published an announcement covering the disposal and outsourcing of manufacturing, signalling that it intends to rely on external partners to produce its devices rather than running all production in-house. Commentary on the first-half figures linked this Manufacturing overhaul to the company's stated path towards profitability.

The company also announced plans for a placing to raise approximately £5.5m, which reports said would support progress on a partial divestment. A subsequent result of placing announcement confirmed the outcome of the fundraising. Separately, Creo issued a commercial update on MicroBlate Fine and later published the result of its annual general meeting.

The theme of the year has been a leaner structure and a sharper focus, reflecting the restructuring.

Financial Picture

According to reports on the H1-26 trading update and interim results, revenue in the first half rose by about 45%, while costs were cut by around 15%. The period was one in which revenue surged and losses narrowed. Full detailed figures, including cash balances, were not available at the time of writing.

Creo does not pay a dividend, which is typical for a growth-stage medical technology company that is still investing in commercialisation and has relied on share funding.

Sector and index Context

Creo is a constituent of the FTSE AIM All Share Index, which tracks companies listed on the London Stock Exchange's growth market. Medical technology developers on AIM often face a long road from regulatory approval to widespread clinical adoption, and many have needed repeated fundraisings along the way. Investor appetite for the sector has tended to depend on clear evidence of revenue traction and a credible route to breakeven.

Key Risks

The company remains loss-making, and further capital could be required if sales growth or divestment proceeds fall short of expectations. Outsourcing manufacturing brings its own execution risks, including reliance on third parties for Supply quality and continuity. Adoption of new endoscopic techniques by hospitals can be slow, and reimbursement and regulatory hurdles vary from market to market. Share placings can also dilute existing shareholders.

What to Watch Next

Investors are likely to watch for progress on the partial divestment, the smooth transfer of production to outsourced partners, and further commercial updates on MicroBlate Fine and the wider product range. The next trading update should show whether the first-half revenue momentum and cost savings have carried through into the second half of the year.